The Interferon Gene Signature as a Clinically Relevant Biomarker in Autoimmune Rheumatic Disease
Lancet Rheumatol 2022;4:e61–72.
The interferon gene signature (IGS) fits into the paradigm of a personalised approach to care in rheumatic diseases, where an individual’s score could inform either prompt diagnosis, early use of certain therapies, or presage specific clinical phenotypes.
A raised whole blood IGS has increasingly been reported in rheumatic diseases as sequencing technology has advanced, yet it’s exact role in the clinical management of these diseases remains unclear.
Cooles and Issacs review how a raised IGS can function as a clinically relevant biomarker, independent of whether it is a bystander effect or a key pathological process.